CA2163032C
(en)
|
1993-06-03 |
2001-02-06 |
John Landon |
Antibody fragments in therapy
|
GB9501683D0
(en)
|
1995-01-27 |
1995-03-15 |
Glaxo Group Ltd |
Substances and their uses
|
US5646036A
(en)
*
|
1995-06-02 |
1997-07-08 |
Genentech, Inc. |
Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
|
US6214344B1
(en)
|
1995-06-02 |
2001-04-10 |
Genetech, Inc. |
Hepatocyte growth factor receptor antagonists and uses thereof
|
US5686292A
(en)
*
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
GB9517538D0
(en)
*
|
1995-08-26 |
1995-10-25 |
Therapeutic Antibodies Inc |
Production and therapeutic combinations, of antibodies
|
US6090382A
(en)
*
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
US6998116B1
(en)
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
HU228630B1
(en)
|
1996-02-09 |
2013-04-29 |
Abbott Biotech Ltd |
Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
|
AU735200B2
(en)
|
1996-04-01 |
2001-07-05 |
Genentech Inc. |
APO-2LI and APO-3 apoptosis polypeptides
|
DK0922102T3
(da)
|
1996-07-03 |
2010-08-16 |
Genentech Inc |
Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
|
US6462176B1
(en)
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
US5990281A
(en)
*
|
1996-09-30 |
1999-11-23 |
Genentech, Inc. |
Vertebrate smoothened proteins
|
US6136958A
(en)
|
1996-09-30 |
2000-10-24 |
Genentech, Inc. |
Antibodies to vertebrate smoothened proteins
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
CA2293724C
(en)
|
1997-06-05 |
2010-02-02 |
Xiaodong Wang |
Apaf-1, the ced-4 human homolog, an activator of caspase-3
|
JP2002508663A
(ja)
|
1997-06-18 |
2002-03-19 |
ジェネンテク,インコーポレイテッド |
Apo−2DcR
|
EP1045906B1
(de)
|
1998-01-15 |
2008-10-15 |
Genentech, Inc. |
Apo-2 ligand
|
ES2331901T3
(es)
|
1998-06-12 |
2010-01-19 |
Genentech, Inc. |
Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la produccion de los mismos.
|
US7192698B1
(en)
|
1999-08-17 |
2007-03-20 |
Purdue Research Foundation |
EphA2 as a diagnostic target for metastatic cancer
|
US6927203B1
(en)
|
1999-08-17 |
2005-08-09 |
Purdue Research Foundation |
Treatment of metastatic disease
|
DK1303293T3
(da)
|
2000-07-27 |
2009-03-30 |
Genentech Inc |
Sekventiel indgivelse af CPT-11 og APO-2L-polypeptid
|
US7101976B1
(en)
|
2000-09-12 |
2006-09-05 |
Purdue Research Foundation |
EphA2 monoclonal antibodies and methods of making and using same
|
CA2425779C
(en)
|
2000-10-12 |
2013-08-06 |
University Of Rochester |
Compositions that inhibit proliferation of cancer cells
|
US6709655B2
(en)
*
|
2001-02-28 |
2004-03-23 |
Instituto Bioclon, S.A. De C.V. |
Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
|
CA2868614A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
EP2075256A2
(de)
|
2002-01-14 |
2009-07-01 |
William Herman |
Gezielte Liganden
|
KR20040096554A
(ko)
|
2002-02-06 |
2004-11-16 |
비코르 테크놀로지스 인코포레이티드 |
경색방지 분자
|
JP2005521429A
(ja)
|
2002-03-25 |
2005-07-21 |
ユーエービー リサーチ ファウンデーション |
Fcレセプターホモログ、試薬およびこれらの使用
|
ATE503233T1
(de)
|
2002-06-14 |
2011-04-15 |
Us Gov Health & Human Serv |
Verfahren zur behandlung und prävention von kolitis, an der il-13 und nk-t zellen beteiligt sind
|
CA2495478A1
(en)
|
2002-08-05 |
2004-02-12 |
University Of Rochester |
Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
US7597936B2
(en)
|
2002-11-26 |
2009-10-06 |
University Of Utah Research Foundation |
Method of producing a pigmented composite microporous material
|
JP4824312B2
(ja)
|
2002-11-26 |
2011-11-30 |
ユニバーシティ オブ ユタ リサーチ ファンデーション |
微小孔物質、被分析物の局在化及び定量の方法、並びに被分析物の局在化及び定量用物品
|
US7335759B2
(en)
*
|
2002-12-02 |
2008-02-26 |
Universidad Nacional Autónoma de Méxica (UNAM) |
Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
|
WO2004050683A2
(en)
*
|
2002-12-02 |
2004-06-17 |
Abgenix, Inc. |
Antibodies directed to tumor necrosis factor and uses thereof
|
US7141015B2
(en)
*
|
2003-05-09 |
2006-11-28 |
Bernard Joseph Ruane |
Expandable and pivotally adjustable surgical retractor
|
DE60331598D1
(de)
*
|
2003-07-25 |
2010-04-15 |
Silanes Sa De Cv Lab |
Verabreichung von anti-tnf-alpha f(ab')2 antikörper-fragmenten
|
FR2859725B1
(fr)
*
|
2003-09-16 |
2006-03-10 |
Neovacs |
Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
|
WO2005069969A2
(en)
|
2004-01-21 |
2005-08-04 |
University Of Utah Research Foundation |
Mutant sodium channel nav1.7 and methods related thereto
|
KR100942849B1
(ko)
|
2004-03-30 |
2010-02-17 |
글락소 그룹 리미티드 |
면역글로불린
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
DK1773885T3
(da)
|
2004-08-05 |
2010-08-16 |
Genentech Inc |
Humaniserede anti-c-met-antagonister
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
WO2006113767A2
(en)
|
2005-04-15 |
2006-10-26 |
Genentech, Inc. |
Hgf beta chain variants
|
US7381802B2
(en)
*
|
2005-04-15 |
2008-06-03 |
Universidad Nacional Autónoma De México (UNAM) |
Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
|
CN102961746B
(zh)
|
2005-05-16 |
2016-06-15 |
艾伯维生物技术有限公司 |
TNFα抑制剂治疗腐蚀性多关节炎的用途
|
EP1931700B1
(de)
|
2005-05-19 |
2013-07-17 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Funktionelle epitope von streptococcus pneumoniae-psaa-antigen und anwendungen davon
|
EP1806365A1
(de)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antikörper spezifisch für Fibroblasten-Aktivierungsprotein und Immunokonjugaten, die diese Antikörper enthalten
|
AU2007223427A1
(en)
|
2006-03-01 |
2007-09-13 |
University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
US8470965B2
(en)
|
2006-03-01 |
2013-06-25 |
University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
CA2911000A1
(en)
|
2006-04-05 |
2007-10-18 |
Min W. Wan |
Antibody purification
|
EP2010214A4
(de)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
Verwendung und zusammensetzungen zur behandlung von rheumatoider arthritis
|
EP2666472A3
(de)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
CN101505795B
(zh)
|
2006-07-03 |
2013-02-13 |
查尔斯·戴维·阿代尔 |
用于调节细胞粘附分子表达的组合物
|
US8999317B2
(en)
|
2006-11-01 |
2015-04-07 |
University Of Rochester |
Methods and compositions related to the structure and function of APOBEC3G
|
US9101671B2
(en)
|
2007-01-03 |
2015-08-11 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to clot binding compounds
|
EP2115173B1
(de)
|
2007-01-08 |
2011-09-21 |
Government of the USA, as Represented by the Secretary, Department of Health and Human Services |
Slco1b3-genotyp
|
US9068003B2
(en)
|
2007-01-10 |
2015-06-30 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
|
US9896511B2
(en)
|
2007-01-10 |
2018-02-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
|
WO2008121437A2
(en)
|
2007-02-08 |
2008-10-09 |
The Burnham Institute For Medical Research |
Trophinin-binding peptides and uses thereof
|
EP2478766A3
(de)
|
2007-05-09 |
2012-08-15 |
Burnham Institute for Medical Research |
Wirtsproteinasen als Ziel für eine therapeutische Strategie gegen virale und bakterielle Krankheitserreger
|
CA2688009C
(en)
|
2007-05-23 |
2019-04-02 |
David E. Briles |
Detoxified pneumococcal neuraminidase and uses thereof
|
NZ581742A
(en)
|
2007-06-08 |
2012-09-28 |
Biogen Idec Inc |
Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
PE20090368A1
(es)
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
PE20140196A1
(es)
|
2007-08-09 |
2014-03-19 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
US8501912B2
(en)
|
2007-12-03 |
2013-08-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Filipil compositions and methods for treating cancer
|
KR20100120289A
(ko)
|
2008-01-15 |
2010-11-15 |
애보트 게엠베하 운트 콤파니 카게 |
분말상 단백질 조성물 및 이의 제조 방법
|
PL2119726T5
(pl)
|
2008-05-14 |
2018-04-30 |
Immatics Biotechnologies Gmbh |
Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu
|
US8946291B2
(en)
|
2008-08-15 |
2015-02-03 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for treating pigmentary conditions and melanoma
|
EP2328928A2
(de)
|
2008-08-25 |
2011-06-08 |
Dana-Farber Cancer Institute, Inc. |
Konserviertes influenzahämagglutininepitop und antikörper dagegen
|
ES2536465T3
(es)
|
2008-10-01 |
2015-05-25 |
Immatics Biotechnologies Gmbh |
Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
|
WO2010065617A1
(en)
|
2008-12-02 |
2010-06-10 |
University Of Utah Research Foundation |
Pde1 as a target therapeutic in heart disease
|
HUE026374T2
(en)
|
2008-12-12 |
2016-05-30 |
Boehringer Ingelheim Int |
Anti-IGF antibody
|
UY32341A
(es)
|
2008-12-19 |
2010-07-30 |
Glaxo Group Ltd |
Proteínas de unión antígeno novedosas
|
WO2011020107A2
(en)
|
2009-08-14 |
2011-02-17 |
Georgetown University |
Compositions and methods for detection and treatment of breast cancer
|
US20110081293A1
(en)
|
2009-10-07 |
2011-04-07 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to clot-binding lipid compounds
|
JP2013510871A
(ja)
|
2009-11-12 |
2013-03-28 |
ジェネンテック, インコーポレイテッド |
樹状突起棘の密度を促す方法
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
US8912136B2
(en)
|
2009-12-18 |
2014-12-16 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to clot-binding compounds
|
AR079944A1
(es)
|
2010-01-20 |
2012-02-29 |
Boehringer Ingelheim Int |
Anticuerpo neutralizante de la actividad de un anticoagulante
|
US8940303B2
(en)
|
2010-01-28 |
2015-01-27 |
Glaxo Group Limited |
CD127 binding proteins
|
US20110207789A1
(en)
|
2010-02-19 |
2011-08-25 |
Ye Fang |
Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
WO2011141823A2
(en)
|
2010-05-14 |
2011-11-17 |
Orega Biotech |
Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
ES2717908T3
(es)
|
2010-06-14 |
2019-06-26 |
Lykera Biomed S A |
Anticuerpos S100A4 y usos terapéuticos de los mismos
|
EP2585145B1
(de)
|
2010-08-19 |
2014-03-05 |
West Pharmaceutical Services, Inc. |
Starrer nadelschutz
|
US9051619B2
(en)
|
2011-03-25 |
2015-06-09 |
Florida Agricultural and Mechanical University (FAMU) |
Methods and compositions for prostate cancer metastasis
|
JP2014515740A
(ja)
|
2011-03-30 |
2014-07-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗凝固薬の解毒剤
|
PL221015B1
(pl)
*
|
2011-04-11 |
2016-02-29 |
Akademia Medyczna Im Piastów Śląskich |
Sposób otrzymywania inhibitorów cysteinowych peptydaz o czystości elektroforetycznej z materiałów biologicznych
|
EP2702077A2
(de)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
|
US20130004484A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
JP6170925B2
(ja)
|
2011-09-30 |
2017-07-26 |
サーコーティン ダイアグノスティックス エルエルシー |
癌のマーカーとしてのbin1の発現
|
US20130122005A1
(en)
|
2011-10-27 |
2013-05-16 |
Paul Adam |
Anticancer combination therapy
|
WO2013088240A1
(en)
|
2011-12-13 |
2013-06-20 |
Sony Corporation |
Memory device
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
CN104662153A
(zh)
|
2012-06-08 |
2015-05-27 |
学校法人近畿大学 |
针对转运体的抗体及其用途
|
WO2014008475A2
(en)
|
2012-07-05 |
2014-01-09 |
The Ohio State University |
Compositions and methods related to viral vaccines
|
KR20150043523A
(ko)
|
2012-09-02 |
2015-04-22 |
애브비 인코포레이티드 |
단백질 불균일성의 제어 방법
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
US20140094383A1
(en)
|
2012-10-02 |
2014-04-03 |
Ohio State Innovation Foundation |
Tethered Lipoplex nanoparticle Biochips And Methods Of Use
|
MX367136B
(es)
|
2012-10-18 |
2019-08-06 |
Inosan Biopharma S A Star |
Proceso para purificar fragmentos de anticuerpos polivalentes derivados de plasma hiperinmune.
|
WO2014085821A2
(en)
|
2012-11-30 |
2014-06-05 |
The Regents Of The University Of California |
Fully human antibodies and fragments recognizing human c-met
|
US20140255413A1
(en)
|
2013-03-07 |
2014-09-11 |
Boehringer Ingelheim International Gmbh |
Combination therapy for neoplasia treatment
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
US9783576B2
(en)
|
2013-06-11 |
2017-10-10 |
Sanford-Burnham Medical Research Institute |
Compositions and methods for targeted endometriosis treatment
|
TWI777197B
(zh)
|
2013-08-05 |
2022-09-11 |
德商伊瑪提克斯生物科技有限公司 |
新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(六)
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
GB201319446D0
(en)
|
2013-11-04 |
2013-12-18 |
Immatics Biotechnologies Gmbh |
Personalized immunotherapy against several neuronal and brain tumors
|
US10203327B2
(en)
|
2013-11-05 |
2019-02-12 |
Novartis Ag |
Organic compounds
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
US10247729B2
(en)
|
2014-05-05 |
2019-04-02 |
Microbplex, Inc. |
Media elaborated with newly synthesized antibodies (MENSA) and uses thereof
|
GB201408255D0
(en)
|
2014-05-09 |
2014-06-25 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
|
GB201411037D0
(en)
|
2014-06-20 |
2014-08-06 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
GB201501017D0
(en)
|
2014-12-23 |
2015-03-04 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
|
WO2016141088A1
(en)
|
2015-03-02 |
2016-09-09 |
Sarcotein Diagnostics, Llc |
13+/17+ bin1 expression as a marker of cardiac disorders
|
MD3388075T2
(ro)
|
2015-03-27 |
2023-10-31 |
Immatics Biotechnologies Gmbh |
Noi peptide și combinații de peptide pentru utilizare în imunoterapia împotriva unor diverse tumori (SEQ ID 25 - MXRA5-003)
|
GB201505585D0
(en)
|
2015-03-31 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
GB201507719D0
(en)
|
2015-05-06 |
2015-06-17 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
MA42294B1
(fr)
|
2015-07-01 |
2020-11-30 |
Immatics Biotechnologies Gmbh |
Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
|
MA51531A
(fr)
|
2015-07-06 |
2020-11-11 |
Immatics Biotechnologies Gmbh |
Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
GB201522667D0
(en)
|
2015-12-22 |
2016-02-03 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
|
GB201602918D0
(en)
|
2016-02-19 |
2016-04-06 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
|
CN116375797A
(zh)
|
2016-03-01 |
2023-07-04 |
伊玛提克斯生物技术有限公司 |
用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
|
EP4219524A3
(de)
|
2016-04-06 |
2023-10-18 |
immatics biotechnologies GmbH |
Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen aml und andere karzinome
|
EP3458478B1
(de)
|
2016-05-18 |
2021-01-06 |
Boehringer Ingelheim International GmbH |
Anti pd-1 und anti-lag3 antikörper zur krebsbehandlung
|
TWI796299B
(zh)
|
2016-08-26 |
2023-03-21 |
德商英麥提克生物技術股份有限公司 |
用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
|
JP7239179B2
(ja)
|
2016-10-05 |
2023-03-14 |
ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション,インコーポレイテッド |
Nk細胞および抗pdl1による癌治療法に関連する方法および組成物
|
EP3360898A1
(de)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
|
MA47111A
(fr)
|
2016-12-22 |
2019-10-30 |
Univ Wake Forest Health Sciences |
Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
|
GB201701404D0
(en)
*
|
2017-01-27 |
2017-03-15 |
Micropharm Ltd |
Therapies for treating inflammatory disorders
|
MA47367B1
(fr)
|
2017-01-27 |
2023-06-28 |
Immatics Biotechnologies Gmbh |
Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
|
WO2018167486A1
(en)
|
2017-03-15 |
2018-09-20 |
Oxford Biomedica (Uk) Limited |
Method
|
JP7159187B2
(ja)
|
2017-03-20 |
2022-10-24 |
バクシネックス インコーポレーティッド |
セマフォリン-4d抗体とエピジェネティック調節剤の組み合わせを用いたがんの処置方法
|
BR112019020386A2
(pt)
|
2017-03-28 |
2020-06-09 |
Mayo Found Medical Education & Res |
vacinas de peptídeos de pd-1 humana e usos das mesmas
|
EP3385699A1
(de)
|
2017-04-07 |
2018-10-10 |
Universitat Rovira i Virgili |
Optofluidische vorrichtung und verfahren zur detektion von zirkulierenden tumorzellen
|
CR20210159A
(es)
|
2017-04-10 |
2021-05-21 |
Immatics Biotechnologies Gmbh |
Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
|
WO2018189152A2
(en)
|
2017-04-10 |
2018-10-18 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
|
WO2018189148A1
(en)
|
2017-04-10 |
2018-10-18 |
Immatics Biotechnologies Gmbh |
Peptides and combination thereof for use in the immunotherapy against cancers
|
SG11201913302SA
(en)
|
2017-07-07 |
2020-01-30 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
|
WO2019007974A1
(en)
|
2017-07-07 |
2019-01-10 |
Immatics Biotechnologies Gmbh |
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
|
WO2019012296A1
(en)
|
2017-07-14 |
2019-01-17 |
The Francis Crick Institute Limited |
ANALYSIS OF HLA ALLELS IN TUMORS AND USES THEREOF
|
US12025615B2
(en)
|
2017-09-15 |
2024-07-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
MX2019015360A
(es)
|
2017-10-02 |
2020-02-07 |
Laboratorios Silanes S A De C V |
Proceso de alto rendimiento para la produccion de antivenenos de fragmentos f(ab')2 de anticuerpos.
|
DE102018107224A1
(de)
|
2018-02-21 |
2019-08-22 |
Immatics Biotechnologies Gmbh |
Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
TW202016131A
(zh)
|
2018-05-16 |
2020-05-01 |
德商英麥提克生物技術股份有限公司 |
用於抗癌免疫治療的肽
|
EP3569618A1
(de)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonisierender cd73-antikörper
|
EP3802616A4
(de)
|
2018-06-04 |
2022-03-30 |
University of Maryland, Baltimore |
Verfahren zur prävention einer akuten nierenläsion
|
US10925947B2
(en)
|
2018-06-29 |
2021-02-23 |
Immatics Biotechnologies Gmbh |
A*03 restricted peptides for use in immunotherapy against cancers and related methods
|
EP3813884A4
(de)
|
2018-06-29 |
2022-03-23 |
North Carolina State University |
In situ gesprühtes bioresponsives immuntherapeutisches gel zur postoperativen behandlung
|
TW202019955A
(zh)
|
2018-07-31 |
2020-06-01 |
德商英麥提克生物技術股份有限公司 |
B*07 限制肽和肽組合的抗癌免疫治療和相關方法
|
US11945850B2
(en)
|
2018-09-17 |
2024-04-02 |
Immatics Biotechnologies Gmbh |
B*44 restricted peptides for use in immunotherapy against cancers and related methods
|
TW202024121A
(zh)
|
2018-09-18 |
2020-07-01 |
德商英麥提克生物技術股份有限公司 |
A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
|
GB201818477D0
(en)
|
2018-11-13 |
2018-12-26 |
Emstopa Ltd |
Tissue plasminogen activator antibodies and method of use thereof
|
WO2020115223A1
(en)
|
2018-12-05 |
2020-06-11 |
Katholieke Universiteit Leuven |
S100a4 as a marker of treatment with spironolactone, pioglitazone and metformin
|
TW202039535A
(zh)
|
2018-12-18 |
2020-11-01 |
德商英麥提克生物技術股份有限公司 |
B*08限制肽和肽組合物抗癌免疫治療和相關方法
|
WO2020225549A1
(en)
|
2019-05-06 |
2020-11-12 |
The Francis Crick Institute Limited |
Method for preventing inflammation
|
MX2021015970A
(es)
|
2019-06-21 |
2022-04-06 |
Vaccinex Inc |
Terapia de combinacion con bloqueo de semaforina-4d (sema4d) y terapia de dc1.
|
CN114423793A
(zh)
|
2019-09-18 |
2022-04-29 |
分子模板公司 |
包含志贺菌毒素a亚基支架的pd-l1结合分子
|
US11918649B2
(en)
|
2019-09-18 |
2024-03-05 |
Molecular Templates, Inc. |
PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
|
TW202128756A
(zh)
|
2019-10-02 |
2021-08-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
EP4038222A4
(de)
|
2019-10-02 |
2023-10-18 |
Arizona Board of Regents on behalf of Arizona State University |
Verfahren und zusammensetzungen zur identifizierung von neoantigenen zur verwendung bei der behandlung und vorbeugung von krebs
|
EP4146327A1
(de)
|
2020-05-08 |
2023-03-15 |
Novocure GmbH |
Zusammensetzungen und verfahren zur anwendung von elektrischen wechselfeldern auf pluripotente stammzellen
|
JP2023504675A
(ja)
|
2020-05-19 |
2023-02-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ガンの処置のための結合分子
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
DE102020125465A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
AR123862A1
(es)
|
2020-10-21 |
2023-01-18 |
Boehringer Ingelheim Int |
Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的hla展示肽
|
CN117957256A
(zh)
|
2021-06-17 |
2024-04-30 |
勃林格殷格翰国际有限公司 |
新颖三特异性结合分子
|
WO2023089131A1
(en)
|
2021-11-19 |
2023-05-25 |
Lykera Biomed, S.A. |
Treatment and diagnosis of diseases associated to pathogenic fibrosis
|
CN114132883B
(zh)
*
|
2021-11-29 |
2023-12-22 |
义乌市奥飞创意设计有限公司 |
一种可降低气溶胶污染的血清蛋白抑制剂注射装载设备
|
WO2024013315A1
(en)
|
2022-07-15 |
2024-01-18 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
WO2024102962A1
(en)
|
2022-11-10 |
2024-05-16 |
Immuvia Inc |
Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
|